GPCR
What one share of Structure Therapeutics holds
Pharmaceutical Preparations
We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (“GPCRs”).
Structure Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.07 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$1.12 |
| Cash and investments | $1.28 |
| Book value | $6.34 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$5.51 | $0.02 | −$4.83 | — | −$10.94 |
| 2023 | — | −$0.81 | $0.02 | −$0.74 | — | $3.25 |
| 2024 | — | −$0.78 | $0.01 | −$0.75 | — | $5.03 |
| 2025 | — | −$0.80 | $0.02 | −$1.27 | — | $7.14 |